Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Peptic Ulcer

Free Subscription Articles published in Aliment Pharmacol Ther Retrieve available abstracts of 42 articles: HTML format

Single Articles

February 2026
1. KITCHEN P, Schutte SL, Tergast TL, Maasoumy B, et al
   Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors.
   Aliment Pharmacol Ther. 2026 Feb 17. doi: 10.1111/apt.70593.
   PubMed     Abstract available
   
   
   January 2026
2. GISBERT JP, Parra P, Nyssen OP
   Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.
   Aliment Pharmacol Ther. 2026 Jan 19. doi: 10.1111/apt.70535.
   PubMed     Abstract available
   
   
   May 2025
3. SPINELLI I, Ianiro G
   Letter: Helicobacter pylori and Eosinophilic Oesophagitis-Lost in Definition? Authors' Reply.
   Aliment Pharmacol Ther. 2025 May 20. doi: 10.1111/apt.70204.
   PubMed    
   
   
   
4. CRISTOFORI F, Dargenio VN, Francavilla R
   Letter: Helicobacter pylori and Eosinophilic Oesophagitis-Lost in Definition?
   Aliment Pharmacol Ther. 2025 May 20. doi: 10.1111/apt.70179.
   PubMed    
   
   
   
5. KAHRILAS PJ, Keefer L, Yadlapati R, Anastasiou F, et al
   Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression.
   Aliment Pharmacol Ther. 2025;61:1437-1446.
   PubMed     Abstract available
   
   
   April 2025
6. SPINELLI I, Ianiro G
   Letter: Meta-Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis. Authors' Reply.
   Aliment Pharmacol Ther. 2025 Apr 10. doi: 10.1111/apt.70135.
   PubMed    
   
   
   
7. RAHMAN H
   Letter: Meta-Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis.
   Aliment Pharmacol Ther. 2025 Apr 10. doi: 10.1111/apt.70122.
   PubMed    
   
   
   
8. SHARMA P, Vaezi M, Unge P, Andersson K, et al
   Clinical Trial: Dose-Finding Study of Linaprazan Glurate, A Novel Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis.
   Aliment Pharmacol Ther. 2025 Apr 4. doi: 10.1111/apt.70109.
   PubMed     Abstract available
   
   
   March 2025
9. SPINELLI I, Ianiro G
   Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis. Authors' Reply.
   Aliment Pharmacol Ther. 2025 Mar 26. doi: 10.1111/apt.70099.
   PubMed    
   
   
   
10. EMANUELE E, Minoretti P
    Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis.
    Aliment Pharmacol Ther. 2025 Mar 26. doi: 10.1111/apt.70075.
    PubMed    
    
    
    February 2025
11. SPINELLI I, Porcari S, Esposito C, Fusco W, et al
    Meta-Analysis: Inverse Association Between Helicobacter pylori Infection and Eosinophilic Oesophagitis.
    Aliment Pharmacol Ther. 2025 Feb 24. doi: 10.1111/apt.70042.
    PubMed     Abstract available
    
    
    
12. MIYAHARA S, Yamashina T, Ohyama T, Banno M, et al
    Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor.
    Aliment Pharmacol Ther. 2025 Feb 14. doi: 10.1111/apt.70011.
    PubMed    
    
    
    
13. CHUAH KH, Mahadeva S
    Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply.
    Aliment Pharmacol Ther. 2025 Feb 14. doi: 10.1111/apt.70025.
    PubMed    
    
    
    January 2025
14. FISCHMAN M, Elias A, Klein A, Cohen Y, et al
    Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30-Day Mortality From Acute Pancreatitis.
    Aliment Pharmacol Ther. 2025 Jan 31. doi: 10.1111/apt.18523.
    PubMed     Abstract available
    
    
    
15. TAYLOR S, Chen L, Dutt K, Boyapati R, et al
    Blood Group B May Reduce Risk of Rebleeding in Patients With Upper Gastrointestinal Haemorrhage due to Peptic Ulcer Disease.
    Aliment Pharmacol Ther. 2025 Jan 9. doi: 10.1111/apt.18485.
    PubMed     Abstract available
    
    
    December 2024
16. ARMSTRONG D, Hungin AP, Kahrilas PJ, Sifrim D, et al
    Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements.
    Aliment Pharmacol Ther. 2024 Dec 30. doi: 10.1111/apt.18420.
    PubMed     Abstract available
    
    
    
17. HOWDEN CW, Katz P, DeVault KR, Metz DC, et al
    Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro-Oesophageal Reflux Disease or Erosive Oesophagitis.
    Aliment Pharmacol Ther. 2024 Dec 25. doi: 10.1111/apt.18458.
    PubMed     Abstract available
    
    
    
18. SCHULZ C, Suerbaum S, Malfertheiner P
    Editorial: Helicobacter pylori Antimicrobial Susceptibility Testing-An Expanding Toolbox. Authors' Reply.
    Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18429.
    PubMed    
    
    
    
19. CHUAH KH, Loo QY, Hian WX, Khoo XH, et al
    Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor.
    Aliment Pharmacol Ther. 2024 Dec 2. doi: 10.1111/apt.18418.
    PubMed     Abstract available
    
    
    September 2024
20. IDALSOAGA F, Diaz LA, Ayares G, Cabrera D, et al
    Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease-Authors' reply.
    Aliment Pharmacol Ther. 2024 Sep 2. doi: 10.1111/apt.18246.
    PubMed    
    
    
    
21. KOUNTOURAS J, Vardaka E, Zavos C, Chatzopoulos D, et al
    Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease.
    Aliment Pharmacol Ther. 2024 Sep 2. doi: 10.1111/apt.18220.
    PubMed    
    
    
    July 2024
22. KOUNTOURAS J, Polyzos SA, Kazakos E, Zavos C, et al
    Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH.
    Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18124.
    PubMed    
    
    
    
23. BANSAL SK, Bansal MB
    'Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18182.
    PubMed    
    
    
    
24. BAGER P, Dahlerup JF
    Letter: Post-endoscopic management after upper gastrointestinal bleeding-Replenishment of iron loss.
    Aliment Pharmacol Ther. 2024 Jul 16. doi: 10.1111/apt.18050.
    PubMed    
    
    
    
25. WANG Y, Pan Y
    Letter: Reflections on the role of over-the-scope clips in high-risk upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2024 Jul 15. doi: 10.1111/apt.18145.
    PubMed    
    
    
    
26. LYU C, Yang D, Xu H, He K, et al
    Letter: Reflections on the role of over-the-scope clips in high-risk upper gastrointestinal bleeding-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 15. doi: 10.1111/apt.18173.
    PubMed    
    
    
    
27. YOON JS, Lee JH
    Letter: Risks of proton pump inhibitor treatment in cirrhotic patients-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 12. doi: 10.1111/apt.18167.
    PubMed    
    
    
    
28. SCHEINER B, Dominik N, Mandorfer M
    Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 3. doi: 10.1111/apt.18144.
    PubMed    
    
    
    
29. KOUNTOURAS J, Polyzos SA, Kazakos E, Papanikolaou IS, et al
    Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease.
    Aliment Pharmacol Ther. 2024 Jul 3. doi: 10.1111/apt.18066.
    PubMed    
    
    
    April 2024
30. WANG J, Wen F, Zhao J
    Letter: Risks of proton pump inhibitor treatment in cirrhotic patients.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17954.
    PubMed    
    
    
    March 2024
31. SHUNG DL, Laine L
    Review article: Upper gastrointestinal bleeding - review of current evidence and implications for management.
    Aliment Pharmacol Ther. 2024 Mar 22. doi: 10.1111/apt.17949.
    PubMed     Abstract available
    
    
    
32. KRAUSE AJ, Yadlapati R
    Review article: Diagnosis and management of laryngopharyngeal reflux.
    Aliment Pharmacol Ther. 2024;59:616-631.
    PubMed     Abstract available
    
    
    February 2024
33. YOON JS, Hong JH, Park SY, Kim SU, et al
    High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.
    Aliment Pharmacol Ther. 2024 Feb 22. doi: 10.1111/apt.17909.
    PubMed     Abstract available
    
    
    
34. LON N, Engel S, Damholt A, Mortensen B, et al
    Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial.
    Aliment Pharmacol Ther. 2024;59:341-349.
    PubMed     Abstract available
    
    
    August 2023
35. GONG EJ, Jung HK, Lee B, Hong J, et al
    Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study.
    Aliment Pharmacol Ther. 2023 Aug 17. doi: 10.1111/apt.17676.
    PubMed     Abstract available
    
    
    July 2023
36. WAUTERS L, Harris PR, Walker MM, Serrano CA, et al
    Letter: childhood recurrent abdominal pain is associated with increased duodenal eosinophilia independent of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023;58:134-136.
    PubMed    
    
    
    May 2023
37. PIOVANI D, Tsantes AG, Schunemann HJ, Bonovas S, et al
    Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication-a retrospective multicentre-cohort analysis. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1199-1200.
    PubMed    
    
    
    
38. KOUNTOURAS J, Papaefthymiou A, Polyzos SA, Kazakos E, et al
    Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities.
    Aliment Pharmacol Ther. 2023;57:1186-1187.
    PubMed    
    
    
    
39. ARAI J, Hayakawa Y, Niikura R, Ihara S, et al
    Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication a retrospective multicentre-cohort analysis.
    Aliment Pharmacol Ther. 2023;57:1196-1198.
    PubMed    
    
    
    April 2023
40. HOWDEN CW, Shah S, Pendse SN, Offman E, et al
    Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17526.
    PubMed     Abstract available
    
    
    
41. SCARPIGNATO C, Howden CW, Leifke E, Mulford DJ, et al
    A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023 Apr 17. doi: 10.1111/apt.17510.
    PubMed     Abstract available
    
    
    March 2023
42. TAILLIEU E, De Witte C, De Schepper H, Van Moerkercke W, et al
    Clinical significance and impact of gastric non-Helicobacter pylori Helicobacter species in gastric disease.
    Aliment Pharmacol Ther. 2023 Mar 28. doi: 10.1111/apt.17488.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum